{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:40:31Z","timestamp":1792546831176,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40265-023-01874-9","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T05:03:20Z","timestamp":1683522200000},"page":"725-729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Omaveloxolone: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"key":"1874_CR1","unstructured":"US Food & Drug Administration. FDA approves first treatment for Friedreich\u2019s ataxia [media release]. 28 Feb 2023. https:\/\/www.fda.gov\/."},{"key":"1874_CR2","first-page":"103","volume":"9","author":"SD Ghanekar","year":"2019","unstructured":"Ghanekar SD, Miller WW, Meyer CJ, et al. Orphan drugs in development for the treatment of Friedreich\u2019s ataxia: focus on omaveloxolone. Degener Neurol Neuromuscul Dis. 2019;9:103\u20137.","journal-title":"Degener Neurol Neuromuscul Dis."},{"key":"1874_CR3","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fncel.2018.00188","volume":"12","author":"R Abeti","year":"2018","unstructured":"Abeti R, Baccaro A, Esteras N, et al. Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich\u2019s ataxia models. Front Cell Neurosci. 2018;12:188.","journal-title":"Front Cell Neurosci"},{"key":"1874_CR4","unstructured":"Reata Pharmaceuticals, Inc. Reata Pharmaceuticals announces FDA approval of SKYCLARYS(TM) (omavaloxolone), the first and only drug indicated for patients with Friedreichs ataxia [media release]. 28 Feb 2023. https:\/\/www.reatapharma.com\/."},{"key":"1874_CR5","unstructured":"Reata Pharmaceuticals, Inc. SKYCLARYS\u2122 (omaveloxolone): US prescribing information. 2023. https:\/\/www.fda.gov\/. Accessed Mar 1 2023."},{"key":"1874_CR6","unstructured":"Abbott Laboratories, Reata Pharmaceuticals, Inc. Abbott and Reata Pharmaceuticals announce agreement to develop and commercialize next-generation antioxidant inflammation modulators [media release]. 12 Dec 2011. http:\/\/www.abbott.com."},{"key":"1874_CR7","unstructured":"Reata Pharmaceuticals, Inc. Reata Pharmaceuticals reacquires rights from AbbVie to develop and commercialize bardoxolone methyl, omaveloxolone, and all next-generation Nrf2 activators [media release]. 10 Oct 2019. http:\/\/www.reatapharma.com."},{"key":"1874_CR8","doi-asserted-by":"crossref","unstructured":"Figueroa F, Salinas L, Montgomery C, et al. Nrf2 agonist omaveloxolone improves cardiac function in mice with Friedreich's ataxia [abstract no. 15376]. In: American Heart Association Scientific Sessions. 2022.","DOI":"10.1161\/circ.146.suppl_1.15376"},{"key":"1874_CR9","doi-asserted-by":"crossref","unstructured":"Figueroa F, Salinas L, Montgomery C, et al. Nrf2 agonist omaveloxolone improves cardiac function in mouse model of Friedreich\u2019s ataxia [abstract no. 498]. In: International Congress for Ataxia Research. 2022.","DOI":"10.1161\/circ.146.suppl_1.15376"},{"issue":"2","key":"1874_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","volume":"89","author":"DR Lynch","year":"2021","unstructured":"Lynch DR, Chin MP, Delatycki MB, et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study). Ann Neurol. 2021;89(2):212\u201325.","journal-title":"Ann Neurol"},{"key":"1874_CR11","doi-asserted-by":"crossref","unstructured":"Lynch D, Goldsberry A, Rummey C, et al. Direct utility of natural history data in analysis of clinical trials: propensity match-based analysis of omaveloxolone in Friedreich ataxia using the FA-COMS dataset [abstract no. 518]. In: International Congress for Ataxia Research. 2022.","DOI":"10.1101\/2022.08.12.22278684"},{"issue":"2","key":"1874_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mds.29286","volume":"38","author":"DR Lynch","year":"2023","unstructured":"Lynch DR, Chin MP, Boesch S, et al. Efficacy of omaveloxolone in Friedreich\u2019s ataxia: delayed-start analysis of the MOXIe extension. Mov Disord. 2023;38(2):313\u201320.","journal-title":"Mov Disord"},{"issue":"1","key":"1874_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/acn3.660","volume":"6","author":"DR Lynch","year":"2019","unstructured":"Lynch DR, Farmer J, Hauser L, et al. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Ann Clin Transl Neurol. 2019;6(1):15\u201326.","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01874-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01874-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01874-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T04:15:34Z","timestamp":1702354534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01874-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1874"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01874-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"8 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}